AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-498-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$474 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions
What is AMAG Pharmaceuticals' stock symbol?
AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."
How were AMAG Pharmaceuticals' earnings last quarter?
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its quarterly earnings data on Thursday, February, 7th. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.98) by $0.38. The specialty pharmaceutical company had revenue of $88.10 million for the quarter, compared to analysts' expectations of $95.21 million. AMAG Pharmaceuticals had a negative return on equity of 17.10% and a negative net margin of 13.07%. The firm's quarterly revenue was down 31.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 EPS. View AMAG Pharmaceuticals' Earnings History.
When is AMAG Pharmaceuticals' next earnings date?
What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?
AMAG Pharmaceuticals updated its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $365-415 million, compared to the consensus revenue estimate of $382.51 million.
What price target have analysts set for AMAG?
9 brokers have issued 12-month price objectives for AMAG Pharmaceuticals' stock. Their forecasts range from $14.00 to $24.65. On average, they expect AMAG Pharmaceuticals' share price to reach $20.2063 in the next twelve months. This suggests a possible upside of 62.4% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.
What is the consensus analysts' recommendation for AMAG Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.
What are Wall Street analysts saying about AMAG Pharmaceuticals stock?
Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "AMAG reported a loss in the fourth quarter, narrower than the Zacks Consensus Estimate while sales missed estimates. The company achieved two key regulatory milestones in 2018, with the FDA approving the label expansions of Feraheme and Makena, and accepting the NDA for Vyleesi. During the second half of 2018, the company broadened its product pipeline by adding two promising development-stage assets — AMAG-423, an orphan drug for the potential treatment of severe preeclampsia and thein-licensing of Intrarosa. The company divested the Cord Blood Registry (CBR) business and strengthened its balance sheet. However, in July, Makena’s generic hit the market, which pulled down the drug’s sales. Feraheme currently competes with IV iron replacement therapies like Venofer, Injectafer, Ferrlecit and their generic versions, among others. Shares of the company have underperformed the industry year to date." (3/20/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Neutral rating and are lowering our PT to $14 from $17. Failure of the post-approval Makena trial is a clear setback for the company. We suspect investors may be increasingly drawn to the stock as one to own given the subsequent devaluation, but that longer-term investing requires some framing of the commercial impact. We believe the trial result reinforces the importance of the next 12-18 months for AMAG to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue." (3/14/2019)
Has AMAG Pharmaceuticals been receiving favorable news coverage?
News coverage about AMAG stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a daily sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of AMAG Pharmaceuticals' key competitors?
Some companies that are related to AMAG Pharmaceuticals include Zai Lab (ZLAB), Allakos (ALLK), Pacira Pharmaceuticals (PCRX), Opko Health (OPK), Puma Biotechnology (PBYI), Prestige Consumer Healthcare (PBH), Gossamer Bio (GOSS), Wave Life Sciences (WVE), Innoviva (INVA), Aimmune Therapeutics (AIMT), Clovis Oncology (CLVS), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Cambrex (CBM) and Phibro Animal Health (PAHC).
What other stocks do shareholders of AMAG Pharmaceuticals own?
Who are AMAG Pharmaceuticals' key executives?
AMAG Pharmaceuticals' management team includes the folowing people:
- Dr. William K. Heiden, CEO, Pres & Director (Age 59)
- Mr. Edward H. Myles, Exec. VP & CFO (Age 47)
- Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Sec. (Age 47)
- Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
- Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 49)
Who are AMAG Pharmaceuticals' major shareholders?
AMAG Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (3.55%), D. E. Shaw & Co. Inc. (3.00%), Connor Clark & Lunn Investment Management Ltd. (2.02%), Royce & Associates LP (1.93%), Great Point Partners LLC (1.92%) and Acadian Asset Management LLC (1.57%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.
Which major investors are selling AMAG Pharmaceuticals stock?
AMAG stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Hourglass Capital LLC, Acadian Asset Management LLC, State Board of Administration of Florida Retirement System, Macquarie Group Ltd., GSA Capital Partners LLP and Voce Capital Management LLC. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.
Which major investors are buying AMAG Pharmaceuticals stock?
AMAG stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Royce & Associates LP, Norges Bank, Robeco Institutional Asset Management B.V., Canada Pension Plan Investment Board, Monashee Investment Management LLC, Two Sigma Investments LP and Squarepoint Ops LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.
How do I buy shares of AMAG Pharmaceuticals?
Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AMAG Pharmaceuticals' stock price today?
One share of AMAG stock can currently be purchased for approximately $12.44.
How big of a company is AMAG Pharmaceuticals?
AMAG Pharmaceuticals has a market capitalization of $431.83 million and generates $474 million in revenue each year. The specialty pharmaceutical company earns $-65,760,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.
What is AMAG Pharmaceuticals' official website?
How can I contact AMAG Pharmaceuticals?
AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]
MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
